良性前列腺梗阻患者行前列腺光选择性汽化术时停用或维持口服抗凝治疗(SOAP)的多中心随机对照试验研究方案
本研究为多中心、开放标签、随机对照试验,计划纳入386例接受口服抗凝药(OAC)治疗的良性前列腺梗阻(BPO)患者,按1:1随机分配至围术期维持或停用OAC两组,比较前列腺光选择性汽化术(PVP)后30天Clavien-Dindo分级并发症发生率,以评估维持OAC的非劣效性。
要点
- 评估PVP围术期维持OAC是否非劣于停用OAC。
- 主要终点为30天Clavien-Dindo分级并发症率。
- 非劣效界值为良好结局比例差异不超过10%。
核心结论
- 本研究旨在评估BPO患者行PVP时围术期维持OAC治疗的非劣效性,结果尚未报告。
研究设计与样本
- 多中心、开放标签、随机对照试验,计划纳入386例接受维生素K拮抗剂或直接口服抗凝药的BPO患者,按1:1随机分配至维持或停用OAC组。
关键数值与推荐
- 主要终点为术后30天按Clavien-Dindo分类的并发症发生率。
- 次要终点为术后30天出血和血栓事件发生率。
- 非劣效界值为良好结局(Clavien-Dindo评分<2)患者比例相差不超过10%,采用双侧95%置信区间,把握度80%。
临床怎么用
- 研究结果可能为BPO手术围术期OAC管理提供高级别证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lower urinary tract symptoms related to benign prostatic obstruction (BPO) are frequent in men aged > 50 years. Based on the use of innovative medical devices, a number of transurethral ablative techniques have recently been developed for the surgical treatment of BPO. In recent years, GreenLight photoselective vaporization of the prostate (PVP) has been considered as a non-inferior alternative to transurethral resection of the prostate. The GreenLight PVP is usually considered as an interesting surgical option for patients treated via oral anticoagulants (OACs) with regard to its haemostatic properties. The aim of this study was to assess the impact of maintaining OAC treatment in patients undergoing PVP. METHODS: This study is a multicentre, open-label, randomized controlled trial (RCT) designed to show the non-inferiority of PVP surgery in patients with BPO treated with OACs. This study is designed to enrol 386 OAC-treated patients (treated with vitamin K antagonists and direct oral anticoagulants) who are undergoing PVP for BPO. Patients will be randomized (1:1) to either maintain or stop OAC treatment during the perioperative course. The intervention group will maintain OAC treatment until the day before surgery and resume OAC treatment the day after surgery, whereas the control group will stop OAC treatment (with or without low-molecular-weight heparin bridging therapy) according to the anaesthesia guidelines. The primary outcome of interest to be assessed is the 30-day complications rate according to the Clavien-Dindo classification. The secondary endpoint will examine the 30-day rate of haemorrhagic and thrombotic events. This study will provide 80% power to show non-inferiority, defined as not worse than a 10% (non-inferiority margin) inferior change in the proportion of patients with good outcomes (Clavien-Dindo score < 2), using two-tailed 95% confidence intervals. DISCUSSION: This first multicentre RCT in the field is underway to evaluate the safety and efficacy of PVP in patients with ongoing OAC therapy. The study results could influence the perioperative management of OACs in BPO surgery with a high level of evidence. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03297281 . Registered on 29 September 2017.
引用
- Charbonneau H, Pasquié M, Peyronnet B, et al. Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (SOAP) surgery for benign prostate obstruction: study protocol for a multicentre randomized controlled trial. Trials. 2018. PMID: 30587221. doi:10.1186/s13063-018-3066-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。